Systemic treatment policies in ovarian cancer: the next 10 years
Systemic treatment policies in ovarian cancer: the next 10 years
复制标题
DOI：
10.1111/j.1525-1438.2003.13356.x
复制
发表时间：
2003-11-01
影响因子：
4.8
通讯作者：
Eisenhauer, EA
中科院分区：
文献类型：
--
作者：
Biagi, JJ;Eisenhauer, EA
在过去的二十年里，治疗政策和实践标准的制定已经正式化。在卵巢癌方面，大多数注意力都集中在一线系统治疗政策的制定上，将生存作为推动变革的主要结果。本综述总结了支持紫杉醇-卡铂作为一线治疗广泛使用的护理标准的证据，以及来自随机研究的一些矛盾数据。此外，还总结了最近完成或正在进行的在紫杉醇-卡铂中添加第三种细胞毒性药物的随机研究。最后，讨论了一些新颖的非细胞毒性方法。未来十年的新护理标准和治疗政策将基于对照研究中生存率改善的高质量证据。许多此类试验目前正在进行或计划中。
Over the past two decades, the development of treatment policies and practice standards has become formalized. In ovarian cancer, most attention has been focused on the development of policies for front-line systemic treatment, using survival as the major outcome that should drive change. This review summarizes the evidence that supported the emergence of paclitaxel-carboplatin as a widely used standard of care for front-line therapy and some of the contradictory data from randomized studies. Furthermore, recently completed or ongoing randomized studies of the addition of a third cytotoxic agent to paclitaxel-carboplatin are summarized. Finally, some novel noncytotoxic approaches are discussed. New standards of care and treatment policies in the next decade will be based on high-quality evidence of improved survival from controlled studies. Many such trials are now ongoing or planned.